Faced with the increasing possibility of staff losses that far exceed original expectations, the European Medicines Agency has been reprioritizing its goals.
With the move from London to Amsterdam, the EMA is identifying activities and projects that can be temporarily suspended or reduced in order to focus remaining staff on covering critical functions for the agency as it addresses the staffing challenges posed by Brexit. Read more about the EMA’s newest business continuity plan and its impact on ongoing Clinical Trials Regulation projects in this article from Pink Sheet.
With the move from London to Amsterdam, the EMA is identifying activities and projects that can be temporarily suspended or reduced in order to focus remaining staff on covering critical functions for the agency as it addresses the staffing challenges posed by Brexit. Read more about the EMA’s newest business continuity plan and its impact on ongoing Clinical Trials Regulation projects in this article from Pink Sheet.
